# US 2005/0033043 A1 · Process for preparing purine nucleosides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0033043 A1
- Document ID: US20050033043A1
- Status: Published application
- Kind: A1
- Application number: 10/755,005
- Filed: 2004-01-09
- Published: 2005-02-10
- Earliest claimed: 2001-08-02
- Assignees: Genzyme Corporation
- Inventors: William Bauta; Brian Burke; Brian Schulmeier; William Cantrell; Dennis Lovett; Jose Puente
- Web page: https://patentgrep.com/patent/US20050033043A1

## CPC

- C07H 19/16: Purine radicals
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein a blocked 2-deoxy-α-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.

## Claims

### Claim 1

A process for the stereoselective preparation of a 2′-deoxy-β-nucleoside of the formula:
wherein, R2 and R3 are independently hydroxy protecting groups, R7 and R8 are independently hydrogen, C1-C4 alkyl, or amino protecting groups, and R11 is a halogen or —NR6R7, wherein R6 and R7 are as described above, comprising reacting a 2-deoxy-α-arabinofuranosyl derivative of the formula:
wherein R9 is a halogen and R2 and R3 are as defined above, with an adenine derivative potassium salt of the formula:
wherein R7, R8 and R11 are as defined above in the presence of a substantially anhydrous solvent, and wherein said 2′-deoxy-β-nucleoside is produced in said substantially anhydrous solvent in a molar ratio of greater than 10:1 relative to the 2′-deoxy-α-nucleoside anomer represented by the formula:

### Claim 2 (depends on 1)

The process of claim 1, wherein said molar ratio of said 2′-deoxy-β-nucleoside to said 2′-deoxy-α-nucleoside is at least 15:1.

### Claim 3 (depends on 1)

The process of claim 1, wherein said molar ratio of said 2′-deoxy-β-nucleoside to said 2′-deoxy-α-nucleoside is at least 20:1.

### Claim 4 (depends on 1)

The process of claim 1, wherein R9 is bromo or chloro.

### Claim 5 (depends on 1)

The process of claim 1, wherein R11 is chloro.

### Claim 6 (depends on 1)

The process of claim 1, wherein R2 and R3 are independently benzyl or acetyl.

### Claim 7 (depends on 1)

The process of claim 1, wherein R7 and R8 are independently hydrogen, acetyl, benzoyl, or trimethylsilyl.

### Claim 8 (depends on 1)

The process of claim 1, wherein said adenine derivative salt is formed in situ in said solvent by the reaction of a potassium base of a pKa in water of 15 or above, with an adenine derivative of the formula:
wherein the reaction mixture is heterogenous in that said adenine base is not totally soluble in said solvent.

### Claim 9 (depends on 8)

The process of claim 8, wherein said potassium base is a hindered potassium base with a pKa in water of 17 or above.

### Claim 10 (depends on 9)

The process of claim 9, wherein said hindered potassium base is potassium t-butoxide or potassium t-amylate.

### Claim 11 (depends on 1)

The process of claim 1, further comprising calcium hydride.

### Claim 12 (depends on 1)

The process of claim 1, wherein said substantially anhydrous solvent is selected from the group consisting of t-butyl alcohol, a mixture of t-butyl alcohol and acetonitrile, a mixture of t-butyl alcohol and dichloroethane, a mixture of dichloroethane and acetonitrile, a mixture of t-amyl alcohol and dichloroethane, a mixture of t-amyl alcohol and acetonitrile, a mixture of t-amyl alcohol, acetonitrile and dichloromethane and a mixture of t-amyl alcohol, acetonitrile and dichloroethane.

### Claim 13 (depends on 12)

The process of claim 12, wherein said solvent is a mixture of t-amyl alcohol, acetonitrile and dichloroethane.

### Claim 14 (depends on 13)

The process of claim 13, wherein the ratio of solvents in said solvent mixture of t-amyl alcohol, acetonitrile and dichloroethane is about 2:1:1 by volume respectively.

### Claim 15 (depends on 1)

The process of claim 1, further comprising purification of said β-nucleoside by recrystallization or preparation of a slurry in an inert solvent.

### Claim 16 (depends on 1)

The process of claim 1, wherein said purification of said β-nucleoside comprises reslurry from methanol.

### Claim 17 (depends on 1)

The process of claim 1, further comprising de-protecting said 2′-deoxy-β-nucleoside of the formula:
to form a 2′-deoxy-β-nucleoside of the formula:
wherein R5is a halogen or —NH2.

### Claim 18

A process for the stereoselective preparation of a 2′-deoxy-β-nucleoside of the formula:
wherein, R2 and R3 are independently hydroxy protecting groups, comprising reacting a 2-deoxy-α-arabinofuranosyl derivative of the formula:
wherein R2 and R3 are as defined above, with 2-chloroadenine, in the presence of a substantially anhydrous solvent, and a hindered potassium base with a pKa in water of 15 or above, and wherein said 2′-deoxy-β-nucleoside is produced in a molar ratio of greater then 10:1 relative to the 2′-deoxy-α-nucleoside anomer represented by the formula:

### Claim 19 (depends on 18)

The process of claim 18, wherein said molar ratio of said 2′-deoxy-β-nucleoside to said 2′-deoxy-α-nucleoside is at least 15:1.

### Claim 20 (depends on 18)

The process of claim 18, wherein said molar ratio of said 2′-deoxy-β-nucleoside to said 2′-deoxy-α-nucleoside is at least 20:1.

### Claim 21 (depends on 18)

The process of claim 18, further comprising reacting said 2-deoxy-α-arabinofuranosyl derivative and said 2-chloroadenine in the presence of calcium hydride.

### Claim 22 (depends on 18)

The process of claim 18, wherein R2 and R3 are independently benzyl or acetyl.

### Claim 23 (depends on 18)

The process of claim 18, wherein said hindered potassium base has a pKa in water of 17 or above.

### Claim 24 (depends on 23)

The process of claim 23, wherein said potassium base is potassium t-butoxide or potassium t-amylate.

### Claim 25 (depends on 18)

The process of claim 18, wherein said substantially anhydrous solvent is selected from the group consisting of t-butyl alcohol, a mixture of t-butyl alcohol and acetonitrile, a mixture of t-butyl alcohol and dichloroethane, a mixture of dichloroethane and acetonitrile, a mixture of t-amyl alcohol and dichloroethane, a mixture of t-amyl alcohol and acetonitrile, a mixture of t-amyl alcohol, acetonitrile and dichloromethane and a mixture of t-amyl alcohol, acetonitrile and dichloroethane.

### Claim 26 (depends on 25)

The process of claim 25, wherein said substantially anhydrous solvent is a mixture of t-amyl alcohol, acetonitrile and dichloroethane.

### Claim 27 (depends on 26)

The process of claim 26, wherein the ratio of solvents in said solvent mixture of t-amyl alcohol, acetonitrile and dichloroethane is about 2:1:1 by volume respectively.

### Claim 28 (depends on 18)

The process of claim 18, further comprising purification of said β-nucleoside by recrystallization or preparation of a slurry in an inert solvent.

### Claim 29 (depends on 28)

The process of claim 28, wherein said purification of said β-nucleoside comprises reslurry from methanol.

### Claim 30 (depends on 28)

The process of claim 28, further comprising de-protecting said 2′-deoxy-β-nucleoside of the formula:
to form a 2′-deoxy-β-nucleoside of the formula:
